Bruce Booth, D.PhilPartner at Atlas Venture
Bruce Booth is a partner and focuses on novel biopharmaceutical products, therapeutic platforms, and innovative biomedical technologies.
Bruce is currently chairman of AvroBio (NASDAQ:AVRO), Kymera Therapeutics, Hotspot Therapeutics, Nimbus Therapeutics, Rodin Therapeutics, and Unum Therapeutics (NASDAQ:UMRX), and serves on the boards of Lysosomal Therapeutics, and Magenta Therapeutics (NASDAQ:MGTA). He previously served on the boards of past Atlas companies Avila (acquired by Celgene), Padlock (acquired by BMS), Prestwick (acquired by Biovail), Stromedix (acquired by Biogen), Zafgen (NASDAQ:ZFGN), miRagen Therapeutics (NASDAQ:MGEN), and a number of other ventures.
Bruce serves as an advisor in various capacities to UCB, Takeda, and the Gates Foundation. He also serves on the board of the National Venture Capital Association and of New England Disabled Sports, a charity dedicated to adaptive sports.
Bruce blogs about biotech and venture capital topics at LifeSciVC.com, which is syndicated on Forbes.
Prior to joining Atlas in 2005, Bruce was a consultant at McKinsey & Company, as well as an investor for Caxton Health Holdings. As a British Marshall Scholar, Bruce received a D.Phil. (PhD) in molecular immunology from Oxford University. His work focused on the study of HIV and tumor immune responses. He received a BS in biochemistry, summa cum laude, from The Pennsylvania State University